Israel

RedHill Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19

Lead Product(s): Opaganib

Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 30, 2020

Details:

RedHill Biopharma has initiated a global Phase 2/3 clinical study evaluating opaganib (Yeliva®) in patients hospitalized with severe SARS-CoV-2 infection (the cause of COVID-19) and pneumonia requiring treatment with supplemental oxygen.

RedHill Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia

Lead Product(s): Opaganib

Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 16, 2020

Details:

The Ministry of Health of the Russian Federation has approved RedHill's Clinical Trial Authorization (CTA) application for a Phase 2/3 study evaluating opaganib (Yeliva®) in patients hospitalized with severe SARS-CoV-2 infection and pneumonia.

RedHill Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK

Lead Product(s): Opaganib

Therapeutic Area: Infections and Infectious Diseases Product Name: Yeliva

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2020

Details:

The Phase 2/3 multi-center, randomized, double-blind, parallel-arm, placebo-controlled study with opaganib aims to enroll 270 severe COVID-19 patients in up to 40 clinical sites across the UK, Italy, Russia and additional countries.

Enlivex Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials

Lead Product(s): Allocetra

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Israel Innovation Authority

Deal Size: $1.5 million Upfront Cash: Undisclosed

Deal Type: Funding April 13, 2020

Details:

The fund is directed towards Enlivex's planned COVID-19 and sepsis clinical programs that will evaluate safety and efficacy of AllocetraTM in both the indications.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

RedHill Biopharma

RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19

RedHill Biopharma

RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia

RedHill Biopharma

RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK

Enlivex Therapeutics

Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials